International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 1 Jan-Feb 2024, pp: 881-887 www.ijprajournal.com ISSN: 2249-7781

Implantable Drug Delivery System and Advance Techniques for Drug Delivery

Mr. Hrushikesh Mahadev, Mr. Pritesh Anil Ghadigaonkar
Gawali, Trinity College of Pharmacy, Pune.
Trinity College of Pharmacy, Pune.

Submitted: 20-01-2024 Accepted: 30-01-2024

ABSTRACT: From a long time ago it has been a "Traditional drug delivery system" which were used frequently and the drug forms use in this is mainly powder or liquid, which is administered orally. But, a many problems come's into existence while administration of these drug (i.e. oral administration) To avoid all these problems the new drug delivery system came into existence. As time passed, there were also a need of a drug which can give a constant release and for a long time span. Therefore, this drug delivery comes into existence and it also be a safe, effective and reliable. The one of the example is the Implantable drug delivery system (IDDS). The main objective of this review is to study the currently availability drug delivery system. The main advantages of thisdrug delivery system is that they produce a local action of a drug and at a uniform rate, less quantity drug is required, less side effects, higher efficacy. Due to advancement of such dosage forms, it is possible to take unstable drugs from once every week to once every year.But one of the disadvantages of this drug delivery system is that it is costly.

KEYWORDS: Implantable drug delivery system, implants, drug delivery system,Implantable pumps, Modulated drug delivery.

I. INTRODUCTION

The drugs which are taken through oral route must be protected against decomposition in the GI tract and also should be absorbed through the membrane. They need to be resistant to hepatic enzymes once they have been absorbed and have entered the portal circulation. The blood levels within the therapeutic range should be guaranteed by the rate of drug absorption and excretion. The quantity of medication that reach to the site of action needs to be sufficient to have the intended therapeutic effect without causing any negative side effects. There are two methods for achieving regulated medication delivery: one is to chemically alter the drug moiety, and the other is to formulate it differently. The main disadvantages of oral dosing is that it takes much more time to pass through GI tract. The next method , in case the drug is not administered orally it gives through parenteral route of administration. Those drugs which cannot be given through oral route are given intravenously. But the action of the drugs in IV route is for short time span therefore the frequent use of injections are required. If injectable controlled-release dosage forms offer the necessary safety and efficacy, they have a higher chance of being commercially successful than other delivery methods. One of the methods of medicine delivery is topical application. But, in this drug delivery there is a less absorption of a drug, due to some physiological characteristics of a drug. The implantable drug delivery system comes into the picture to overcome all these problems which are occurring, in oral, intravenous and topical drug administration.

For the combination of various physicochemical characteristics with various therapeutic agents, a number of additives are used how a days. Therefore the mostly available implantable drugs contain active ingredient in a rate controlling system. Implantable drugs are in various shape and sizes. The oral drug delivery system is good but the drug can get digested in GI tract. Drug delivery by injections can also have disadvantages. As a result, patients have to decide between keeping up with their home supplies and traveling to the treatment facility. Inadequate patient compliance may also result from receiving injections frequently. As a result, administering a multiple scheduled drug injection regimen is challenging and necessitates the assistance of a clinician. When other modes of distribution are not preferred or may not be feasible, fully implanted medication delivery systems are ideal. These are the devices that administer drugs to their effective

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 1 Jan-Feb 2024, pp: 881-887 www.ijprajournal.com ISSN: 2249-7781

sites. The pace of drug delivery can be accurately controlled with the help of implanted drug delivery. To sustain a therapeutic level for an extended duration, several therapies necessitate the continual delivery of medicines.

When the oral drug delivery is not suitable then the transdermal, intravenous, pulmonary and implantable system are developed. Implantable drug delivery devices are therefore preferred in situations where patient compliance is achieved. These devices delivers a drug at specific targeted site and at specific rate.

There have been two main obstacles in this field of controlled drug delivery during the last twenty years. Achieving a drug's continuous zeroorder for an long period of time is one of them. This is complicated with the technologies such as osmotic pumps, matrices with controllable swelling, non-uniform drug loading profiles, erosion rates and multi-layered matrices. The second issue concerns the deliberate delivery of a therapeutic agent, such as a protein, in a pulsatile or staggered manner. Two distinct approaches have been thoroughly examined as potential solutions to these demands. One is the creation of a delivery system that delivers its payload in short bursts according to a predefined sequence or at certain intervals. The other is building a system that can adjust to changes in its immediate surroundings. It has been shown that these systems are capable of adjusting the rate at which medications are administered in response to a wide range of stimuli, such as the presence or absence of molecules, light, temperature, ultrasound, electric and magnetic fields, and so on.

CLASSIFICATION OF IMPLANTABLE DRUG DELIVERY SYSTEM

Systems for drug implants can be broadly divided into passive and active categories. Nondegradable and degradable implants are two further categories into which passive systems can be divided. There are two types of active systems: propellent infusion and osmotic infusion.

Passive Implants:-

These consist of simple, singular or homogenous devices. They consist of a drug simply packed in a biochemical matrix. They operate on the principle of passive diffusion and have no moving parts. As the name suggests, medication is delivered passively. A substance diffuses passively when it moves from a high concentration to a low concentration without using any energy. The drug's concentration, drug selection, matrix material, and surface characteristics all affect the drug's delivery kinetics.

a)Biodegradable Implants:-

This systems are prepared by using polymers such as polylactic acid (PLA) , polylactic co glycolic acid (PLGA), polycaprolactone (PCL).The biocompatible polymers utilized in the construction of these delivery systems eventually decompose into harmless metabolites that the body can either absorb or eliminate. Biodegradable polymers have labile bonds, like amide, anhydride, and ester bonds, that are easily broken down by hydrolysis or enzymes There is no need to remove this devices after complete release because they are biodegradable and due to which it improves patient acceptance and compliance. Biodegradable devices are easily fabricated by using methods like melt extrusion, solvent, evaporation and compression molding.

Gliadle Wafer:-It is an implanted, biodegradable medication delivery system. It is made up of biodegradable polyanhydride disks that are 1.45 cm in width and 1.0 mm thick. These disks are intended to be used to inject carmustine or BCNU, a chemotherapy medication, straight into the cavity that is left behind after the tumor is surgically removed. The primary role of the bio-degradable polyanhydride copolymer, which has a 20:80 polypropane:sebacic acid ratio, is to regulate the local distribution of carmustine.

Zoladex:-Additionally, goserelin acetate, a decapeptide counterpart of lutinizing hormone-releasing hormone, is present in this biodegradable implant. It makes use of PLA or PLGA as a carrier, and a hot-melt extrusion process to distribute the medication throughout the polymer matrix. Prefilled syringes containing implants are distributed for commercial use. In this, the medication is released consistently over the course of one to three months.

b)Nondegradable Implants:-

Reservoir type and matrix controlled systems are commonly utilized in this Elastomers, including vinylidene fluoride, acrylates, urethanes, and their copolymers, as well as PEVA, are frequently utilized as matrix or membrane materials. Matrix controlled systems: In these, the medication is usually distributed uniformly throughout the matrix substance. Systems known as reservoirs: in these, the main medication is encased in a permeable and nondegradable membrane, the

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 1 Jan-Feb 2024, pp: 881-887 www.ijprajournal.com ISSN: 2249-7781

thickness and permeability of which regulate the drug's internal diffusion.

Norplants:-It is an implantable nondegradable reservoir. It comes in 6thin, flexible silicone capsules which containing 36 milligrams of the medication. Both extremities are enclosed. The membrane's thickness regulates how quickly drugs are released. They can provide contraceptive protection for up to five years and are usually placed inside the upper arm of female users.

Implanon:-It is also a nondegradable reservoir implant. It consists of a one rod implant (length 4cm, width 2mm) and it comprises of a PEVA which encapsulates 68mg of etonogestrel and releases for 3 years.The thickness of the PEVA membrane covering the rod affects how quickly drugs are released.

Active Implants:-
Dynamic implant system bridle a positive main impetus to empower and control drug discharge. Subsequently, these are commonly ready to regulate drug dosages and conveyance rates considerably more exactly than detached systems. However, this comes at a greater expense, both as far as intricacy and genuine gadget cost.

a)Osmotic pumps:-

Wide worthiness among all dynamic IDDSS. It has a drug storage tank with a semipermeable coating around it that allows surrounding liquids to slowly seep into the supply via osmosis. Because of the hydrostatic strain based on the medication reservoir, a steady efflux of the drug then occurs through the medication entrance, an opening in the film. Drug discharge is maintained at a nearly constant or zero-request rate until all of the medication included in the supply has been consumed.

DUROS Delivery system
ALZET Delivery system
DUROS Delivery system:-

The device is shaped like a circle and has a water-porous membrane covering one side of an idle titanium composite supply. On the other hand, the supply is covered by a dispersion mediator, which liberates the drug definition from the medicine repository. The chamber's length is typically 45 mm and its width ranges from 4 to 10 mm, while smaller or larger structures may be designed depending on the insertion site and pharmaceutical stacking requirements. The chamber houses the cylinder, osmotic motor, and drug definition. The cylinder seals the osmotic motor compartment from the medication repository and separates the medication definition from the osmotic motor.

ALZET Delivery system:-

This device operates through osmotic uprooting and has a regulated rate of delivery over a period of 24 hours to six weeks. The drug which are going to be delivered is put into a central reservoir, which is separated from an osmotic saltfilled chamber by a semi-permeable screen. Water enters the siphon through the semipermeable layer due to the more concentration of salt present in a chamber around the repository. The water portion increases the salt chamber's capacity, which increases the pressure in the flexible storage and allows the drug arrangement to be transported into the host cell through the output port.
Avoids" starting burst impact"
Length: 1.5-5.1cm, Distance across: 0.6-1.4cm
Flow moderator: Polyethylene, styrene acrylonitrile, SS304; External layer: cellulose ester, Medication repository: thermoplastic hydrocarbon elastomer.

b)Propellant infusion pumps:-

In order to generate a constant specific strain for zero-request release, fuel gas is used instead of an osmotic specialist. It is possible to store and release a greater volume of medication when using a compactable medium, such as gas. A fixed-rate pump that is entirely implanted is called Infusaid. The drug detailing chamber and the fluorocarbon charge chamber are divided by a metal partition housed in a titanium enclosure featuring a round shape. The framework includes a stream restrictor to guarantee a steady fume tension from the charge at operational temperatures. Its typical dimensions are 3 cm in height and 9 cm in width. It has been used in the administration of insulin, anticoagulant medication, and chemotherapy to treat cancerous growths. The use of mechanical siphons powered by electricity that typically have moving parts and a sophisticated control system. ChipRx is a single-repository implanted gadget. The release mechanism makes use of polymeric artificial muscles that encircle and regulate minuscule apertures, which then contract to release the medication. The polymeric ring expands or contracts in response to an electrical signal that passes via a swellable hydrogel and a

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 1 Jan-Feb 2024, pp: 881-887 www.ijprajournal.com ISSN: 2249-7781

guiding polymer.

DRUG RELEASE FROM IMPLANTABLE DRUG DELIVERY SYSTEM

Fig. Drug release from implantable DDS

Osmotic pumping and passive diffusion, has been the best in conveying drug in a direct cycle, where's the medication measurement delivered is corresponding to square base of the delivery time. Swelling control, dissolvable entrance into the grid of the medication gadget is typically a lot more slow than dispersion of the medications, which then, at that point, brings about a brought down discharge rate. Osmotic standard can give a consistent delivery rate. The discharge energy of medications from frameworks intervened by osmotic strain, enlarging, and detached dissemination rely upon the dissolvability and dispersion coefficient of the drug in the polymer, the medication load and the in vivo debasement pace of a polymer.

METHODS OF IMPLANTS MANUFACTURING



Fig. Methods of implants manufacturing

Biodegradable polymeric matrices:-

Drug release is controlled by either degradation or dispersion, or by combining the two in biodegradable polymeric structures.

Surface degradation: Surface-to-volume proportion and the calculation of inserts influences drug discharge. The debasement is limited to the external surface of the gadget.

Bulk degradation: The corruption is almost homogeneous all through the material in a mass debasing polymer. The instrument happens when the dissemination pace of a medication is not exactly the corruption or disintegration pace of a polymer transporter. The medication is delivered. simultaneously with the polymer degradation. Drug discharge in view of the corruption controlled system can likewise be partitioned into surface-debasing methodology and mass corrupting approach. The presence of water in the material is a critical factor for polymers that are susceptible to hydrolytic degradation. Water plays a fundamental role in adjusting delivery kinetics and corruption. Polymers that resemble semi-glass degrade in two stages. Water is mixed into the undefinable districts to initiate the first step, which causes irregular hydrolytic cleavage of labile ester securities at the boundaries. The debasement of entire expanses within the formless regions characterizes the second stage. Compared to the first backbone, the polymer chain's breakdown sections are essentially more constrained. This resultant reduction in the normal sub-atomic load of the polymer might be utilized a measurement to evaluate the degree of degradation. Implants containing exceptionally water dissolvable medications showed a huge introductory burst discharge, trailed by a quick release. The drug stacking an affects the delivery rates, with quick delivery being seen from inserts manufactured with high medication stacking.

APPLICATION OF IMPLANTABLE DRUG DELIVERY SYSTEM

Cancer: The implantable medication conveyance framework has extraordinary potential to convey can possibly convey chemotherapeutic medications securely and actually the impacted side without bringing on any incidental effect. Cerebrum, prostate and bladder disease are not many models for which the inserts are accessible in market. The Gliadel wafer endorsed one of the primary implantable cerebrum malignant growth treatment to convey chemotherapy straight forwardly to the

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 1 Jan-Feb 2024, pp: 881-887 www.ijprajournal.com ISSN: 2249-7781

cancer site. Another model the zoladex biodegradable implantable pole conveying goserelin acetic acid derivation for treating prostate disease.

Ocular Therapy: Different implantable frameworks, including layer controlled gadgets implantable silicone gadgets and implantable implantation frameworks have been explored to give drag out visual drug conveyance. Ocusert is an example of a film-controlled framework. It is a pharmaceutical supply that contains alginic corrosive and pilocarpin base, and it is encased in an ethylene-vinyl acetic acid derivation layer that regulates the administration pace. For seven days, this framework delivers 20–40 micrograms of pilocarpin hourly at zero request, after an initial burst. Ocusert is welltolerated in grown-ups, and gives a palatable control of intraocular strain with irrelevant aftereffects; yet, it is ineffectively endured in geriatric where a large portion of the helpful need exists.

Contraception: FDA has as of late supported promoting of Norplant, a sub-dermal embed for long haul conveyance of levonorgestrel (preventative specialist). This gadget comprise of six silicon film cases, each containing 36mg of levonorgestrel, which are set sub-dermally within upper arm or lower arm in fan shape design through a trocar structure a solitary trocar section point. Aggregately these containers convey 70 micro grams each day (in vivo) for the first 100 days with a consistent decline to 30 micro grams each day at around 800 days, this conveyance rate constant for a considerable length of time. Other polymer-based framework being read up for contraception incorporate vaginal ring of silicon elastic, which is utilized for 3-6 months with an expulsion time of multi week month to month during feminine cycle; progestasert, an intrauterine medication discharge gadget of ethylene vinyl acetic acid derivation copolymer, which least for a long time and suspension of injectable microspheres or bars of bio-degradable polymers.

Dental application: Polymeric inserts have been evaluated for a variety of dental applications, such as the adjacent delayed organization of fluoride antibacterial and anti-toxins. For the purpose of supported discharge fluoride conveyance, stannous fluoride was incorporated into different dental concretes. Another one, disposed in different proportions to be a rate-restrictor in drug discharge, is coated with an exterior layer of a copolymer akin to the hydroxyethal methacrylate and methyl methacrylate copolymer hydro gel. The device, which was attained to the buccal upper layer of the maxillary first molar and measured around 8 mm in length, contained 42 mg of fluoride. Its 30-day targeted dosage was 0.5 mg of fluoride per day.

II. FUTURE PROSPECTIVE

Many studies are being carried out in this field of implantable drug delivery at the moment. In spite of Considering this, a lot of work needs to be done in the regions. biocompatible and biodegradable material, the drug release kinetics, as well as additional advancements in the current systems prior to numerous of these preparations are applicable. According to the feature, researchers are still expecting a lot of these systems to be pre-best zeroorder release kinetics compared with in vivo for longperiods of time, allowing for long-term use and constant readiness. A number of these med-Icines are constantly being created from peptides and proteins,whichwhen consumed, are extremely not suitable by oral means. It will be possible to use cutting-edge prolonged-release drug delivery technology to provide such a medication at consistent rates for a protracted amount of time. Length of time and will eliminate the need for several doses. Anticipatedly, in the forthcoming years, new implantable system advancements will assist in lowering cost oftreatment, raise the efficiency of medications and improve compliance of the patient.

III. CONCLUSION

Developing new drug is an expensive and time-consuming procedure. It has been tried to increase the safety and the efficacy ratio of “old” medications using different various techniques, like customizing medication therapy, therapeutic medication monitoring, and dose titration. Delivering medication slowly, at a controlled rate, and gotten delivery is another incredibly alluring way to have also been actively pursued. IDDSs have been a modality of enhanced drug therapy with some degree of clinical and commercial success. However, performance characteristic optimization, excluding drug release and long-term biocompatibility Kinetics is important. Additionally, clinical confirmation of Presently being developed systems are crucial for regulatory compliance as well as their financial performance. But as this review notes, many commercial systems can achieve almost perfect zero-order profiles of release kinetics in vivo, over a prolonged duration times. IDDSs thus offer a practical, economicaltive and medically approved substitute method of

administered medication to patients with long-term illnesses.

REFERENCES

[1]. Vyas SP and KharRoop K; Controlled Drug Delivery Concepts and Advances, Vallabh Prakashan (Delhi);2008, 1st Ed, 450-459.

[2]. Yang L, Fassihi R; Modulation of Diclofenac Release from a Totally Soluble Controlled Release Drug Delivery System, J. Controlled Release; 1997, 44: 135–140.

[3]. Evans AT, Park JM, Chiravuri S, and Gianchandani YB; Dual Drug Delivery Device for Chronic Pain Management using Micromachined Elastic Metal Structures and Silicon Microvalves, Micro Electro Mechanical Systems; 2008, 252-55.

[4]. Kumar, A., & Pillai, J. (2018). Implantable drug delivery systems. In Elsevier eBooks (pp. 473–511). https://doi.org/10.1016/b978-0-12-813665-2.00013-2

[5]. Lee ES, Kim SW, Kim SH, Cardinal JR, Jacobs H; Drug Release from Hydrogel Devices with Rate-Controlling Barriers, J. Membr. Sci.;1980,7:293–303.

[6]. M. F. Samad and A. Z. Kouzani; "Integrated Microfluidic Drug Delivery Devices: A Component View", Microsystem Technologies, vol. 19(7), pp. 957-970, 2013.

[7]. Sefton MV; Implantable Pumps, CRC Crit. Rev.Biomed. Eng.; 1987, 14: 201–240.

[8]. Qiu Y, Chidambram N, Flood K; Design and Evaluation of Layered Diffusional Matrices for Zero-Order Sustained Release, J. Controlled Release; 1998, 51: 123–130.

[9]. Said, S. S., Campbell, S., & Hoare, T. (2019). Externally addressable smart drug delivery Vehicles: current technologies and future directions. Chemistry of Materials, 31(14), 4971–4989. https://doi.org/10.1021/acs.chemmater.9b01798.

[10]. Lu S, Ramirez F, Anseth K; Photopolymerized,Multilaminated Matrix Devices with Optimized Non-Uniform Initial Concentration Profiles to Control Drug Release, J. Pharm. Sci.; 2000, 89.

[11]. Vyas SP and KharRoop K; Controlled Drug Delivery Concepts and Advances, Vallabh Prakashan (Delhi);2008,1st Ed, 473-474.

[12]. T. Goettsche, J. Kohnle, M. Willmann, H. Ernst, S. Messner, R. Steger, M. Storz, W. Lang, R.Zengerle, H. Sandmaier, Novel Approaches to Microfluidic Components in High-End Medical Applications, Proceedings of Transducers03, Boston, Mass., USA, 2003, 623-626.

[13]. Bajpai PK (1989) Ceramic implantable drug delivery system. Trend Biomat Art Org 3:50–60.

[14]. Brown LR, Wei CL, Langer R (1983) In vivo and in vitro release of macromolecules form polymeric drug delivery systems. J Pharm Sci 72:1181–11.

[15]. Dash, A. K., & Cudworth, G. C. (1998). Therapeutic applications of implantable drug delivery systems. Journal of Pharmacological and Toxicological Methods, 40(1), 1–12. https://doi.org/10.1016/s1056-8719(98)00027-6.

[16]. Chowdhary, S.A., Ryken, T., and Newton, H.B., Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis, J. Neuro-Oncol. 122 (2015) 367-382.

[17]. Zhao, D., Tang, Q., Zhou, Q., Peng, K., Yang, H., and Zhang, X., A photo-degradable injectable self-healing hydrogel based on star poly(ethylene glycol)-b-polypeptide as a potential pharmaceuticals delivery carrier, RSC Soft Matter Ser. 14 (2018) 7420-7428.

[18]. Turok, D.K., Gawron, L.M., and Lawson, S., New developments in long-acting reversible contraception: the promise of intrauterine devices and implants to improve family planning services, Fertil. Steril. 106 (2016) 1273-1281.

[19]. n, W., Jiang, H., Wu, X., Xu, Z., Yao, C., Wang, J., Qin, M., Jiang, Q., Wang, W., Shi, D., and Cao, Y., Strong dual-crosslinked hydrogels for ultrasound-triggered drug delivery, Nano Res. 12 (2019)

[20]. Minko, T., Drug delivery systems, in: Sinko, P.J. (Ed.), Martin's Physical Pharmacy and Pharmaceutical Sciences,

Lippincott, Williams & Wilkins, Baltimore, MD, 2006, pp.629-680.

[21]. Santos, A., Sinn Aw, M., Bariana, M., Kumeria, T., Wang, Y., and Losic, D., Drug-releasing implants: current progress, challenges and perspectives, J. Mater. Chem. B 2 (2014) 6157-6182.

[22]. Li, C., Wang, J., Wang, Y., Gao, H., Wei, G., Huang, Y., Yu, H., Gan, Y., Wang, Y., Mei, L., Chen, H., Hu, H., Zhang, Z., and Jin, Y., Recent progress in drug delivery, Acta Pharm. Sin. B 9 (2019) 1145-1162.

[23]. G.V., Implantable drug delivery devices market analysis report by type (biodegradable, non-biodegradable), by product, by technology (diffusion, osmotic, magnetic), by application, and segment forecasts, 2018 – 2025, Market Analysis Report, Grand View Research, San Francisco, CA, (2018), pp. 1-132.

[24]. Khar RK, Vyas SP; Targeted and Controlled Drug Delivery Novel Carrier Systems, CBS Publishers and Distributors: New Delhi; 2002,1st Ed, 384.

[25]. Jain NK; Advances in Controlled & Novel Drug Delivery, CBS Publication, & Distributors; New Delhi;2005, 1st Ed, 219-223.

[26]. Dash AK, Cudworth GC 2nd. Therapeutic applications of implantable drug delivery systems. J Pharmacol Toxicol Methods. 1998 Jul;40(1):1-12. Doi: 10.1016/s1056-8719(98)00027-6. PMID: 9920528.